A Drug for the Prevention and Treatment of Mastitis in Cows

Objects of intellectual property rights

LV15071 B. Composition for the treatment and prevention of sub-clinical mastitis in cows / Jevgeņijs Jermolajevs, Lilija Peškova, Gundega Gulbe, Vaira Saulīte, Simona Doniņa, Anda Valdovska. Owner: Rīga Stradiņš University. Patent publication date: 20.02.2016.; Application no. P-15-67. Application date 14.07.2015.
 

News

Mastitis, or inflammation of the udder, is one the most common diseases in dairy cattle. It is the main cause of economic loss in milk production worldwide. Traditionally, antibiotics are used to treat mastitis. Antibiotics are, however, not always effective. In addition, the use of antibiotics in treating food-producing animals in organic farming is very limited and causes additional loss for the owner.

A group of researchers from Rīga Stradiņš University (RSU) have developed a composition of natural components for the treatment of sub-clinical mastitis in cows. The composition contains lactic acid, lysozyme and natural glycopeptides derived from lactic acid bacteria. 

Description of the stage of development and results

• In vitro experiments have been conducted;
• in vivo experiments have been conducted;
• the components of the new composition and their mutual relation have been selected and studied;
• a method for making a composition has been developed;
  stability studies have been performed on the composition;
• guidelines for the correct use of the composition to treat sub-clinical mastitis have been drawn up.

Features and benefits

• In vitro and in vivo studies show a positive effect in the treatment of sub-clinical mastitis in cows (reduction of pathogenic and conditionally pathogenic bacteria, as well as somatic cells in milk);
• administration of the composition causes a balanced inflammatory response with the activation of cellular immunity locally in the mammary glands, characterised by an increased count of somatic cells and anti-inflammatory cytokine IL-10 activity in leukocytes, resulting in an immediate  reduction of pathogenic and conditionally pathogenic bacteria (on the 3rd day following the first infusion) and a decrease in average somatic cell count (on the 9th day following the last infusion);
• following the administration of the composition, temporary changes in the blood parameters have been observed in the cows that are within the limits of the physiological norm, and are aimed at ensuring immune cell migration, which contribute to the treatment of sub-clinical mastitis locally in the mammary glands;
• in some cases, the use of the composition causes small, temporary changes in the quality of milk;
• the composition can be used in organic farming.

Offer

Selling intellectual property rights or licensing opportunities for licensing development:

• upfront payment
• annual minimums
• milestone payments